This is a study to learn more about the safety and effectiveness of PT217 to treat advanced cancers. We are looking for patients with small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer or gastroenteropancreatic neuroendocrine carcinomas to take part.
Thank you for your interest, but this study is not currently enrolling.
United States (Nationwide)
Jared Weiss
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Phase 1 Trials (all cancers))
23-1716
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
